Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche India MD Girish Telang On Modifying Business Plans In India According To The Environment: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Roche India Managing Director Girish Telang has two difficult issues to handle. On the one hand, Telang has to work closely with his global team to develop the market for Roche in India and at the same time he has to ably fend off objections raised for Roche products through contentious patent battles with Indian companies. In an interview with PharmAsia News, Dr Telang outlines his concerns and reveals how India is placed to take his company's plans forward.

You may also be interested in...

A Change Of Plans: Roche Teams Up With Emcure For Low-Cost Herceptin, Mabthera In India

The Swiss pharma has changed up its strategy in India in an effort to boost volumes.

India’s Supreme Court Directs Patent Office To Review Roche's Valcyte Before Jan. 31

MUMBAI - India's Supreme Court has directed the Controller General of Patents, Designs and Trade Marks to finalize the patent validity of Roche's Valcyte (valganciclovir) before Jan. 31, 2009. Roche had filed a special leave petition that contested the Madras High Court's earlier decision that directed the Indian patent office to review the product patent granted to Valcyte in 2007

Roche Gears Up To Launch Actemra; Lines Up More Clinical Research In India

MUMBAI - Unperturbed by the spate of patent litigations, Swiss drug maker Roche is planning to bring into India Actemra (tocilizumab), its biological therapy indicated for the treatment of rheumatoid arthritis in adults and children

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts